Cheng-Jung Sung

Dr. Cheng-Jung Sung

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JTJennifer Tisoncik-Go
Jennifer Tisoncik-Go
CSCaleb Stokes
Caleb Stokes
LWLeanne S. Whitmore
Leanne S. Whitmore
DNDaniel J. Newhouse
Daniel J. Newhouse
KVKathleen Voss
Kathleen Voss
MGMichael Gale
Michael Gale
Zika virus (ZikV) infection during pregnancy can cause congenital Zika syndrome (CZS) and neurodevelopmental delay in infants, of which the pathogenesis remains poorly understood. We utilize an established female pigtail macaque maternal-to-fetal ZikV infection/exposure model to study fetal brain pathophysiology of CZS manifesting from ZikV exposure in utero. We find prenatal ZikV exposure leads to profound disruption of fetal myelin, with extensive downregulation in gene expression for key components of oligodendrocyte maturation and myelin production. Immunohistochemical analyses reveal marked decreases in myelin basic protein intensity and myelinated fiber density in ZikV-exposed animals. At the ultrastructural level, the myelin sheath in ZikV-exposed animals shows multi-focal decompaction, occurring concomitant with dysregulation of oligodendrocyte gene expression and maturation. These findings define fetal neuropathological profiles of ZikV-linked brain injury underlying CZS resulting from ZikV exposure in utero. Because myelin is critical for cortical development, ZikV-related perturbations in oligodendrocyte function may have long-term consequences on childhood neurodevelopment, even in the absence of overt microcephaly.

24 October 2024 in Genes
Verified
Journal Article
Open access
PDF file
CSCheng-Jung Sung
Cheng-Jung Sung
RKRoshan Kulkarni
Roshan Kulkarni
AHAndrew Hillhouse
Andrew Hillhouse
CSCharles E. Simpson
Charles E. Simpson
JCJohn Cason
John Cason
MBMark Burow
Mark Burow
The identification of informative molecular markers is useful for linkage mapping and can benefit genome-wide association studies by providing fine-scale information about sequence variations. However, high-throughput genotyping approaches are not cost-effective for labs that require frequent use, such as breeding programs that need to perform genotyping on large populations with hundreds of individuals. The number of single nucleotide polymorphism markers generated by those approaches can be far more than needed for most breeding programs; instead, breeders focus on the use of at most hundreds of polymorphic molecular markers for analysis. To help make use of molecular markers a routine tool for breeding programs, we aim to develop a cost-effective genotyping system by using the Tecan Allegro Targeted Resequencing V2 kit. This provides a customized probe design, which indicates that all the DNA fragments synthesized are known targets. SNPs obtained from previous peanut next-generation sequencing data were pre-filtered and selected as targets. These SNP targets were polymorphic among different tetraploid accessions and were selected to be distinguishable from paralogs. A total of 5154 probes were designed to detect 2770 SNP targets and were tested on 48 accessions, which include some closely related sister lines from a breeding population. The results indicated that genotyping by a targeted resequencing approach reduced the cost from around USD 28 (SNP chip and GBS) to USD 18 per sample, while providing polymorphic markers with accurate SNP calls. With this cost-effective genotyping platform, pre-selected SNP markers can be used effectively and routinely for more breeding programs.

9 September 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
YAYuta Asano
Yuta Asano
JVJoshua R. Veatch
Joshua R. Veatch
CSCheng-Jung Sung
Cheng-Jung Sung
TTTzu-Hao Tang
Tzu-Hao Tang
FMFrancesco Mazziotta
Francesco Mazziotta
ACAude G. Chapuis
Aude G. Chapuis
Immune checkpoint inhibitors (ICIs) have transformed Merkel cell carcinoma (MCC) outcomes, but most patients with MCC develop resistance. We identified T cell receptor (TCR) MCC1 , a highly avid, HLA-A*02:01–restricted TCR targeting the Merkel cell polyomavirus (MCPyV) oncoprotein large-T antigen 15–23 . Seven patients with ICI-refractory metastatic MCPyV + MCC received TCR MCC1 -transduced cells (T TCR-MCC1 cells) after lymphodepleting chemotherapy or HLA-enhancing interventions [radiation or interferon gamma-1b (Actimmune)], with concurrent ICIs (NCT03747484). T TCR-MCC1 cells trafficked to tumor sites and expressed a gene expression profile compatible with T cell activation, with tumor regression observed in two patients. However, therapeutic activity was limited by HLA class I silencing, a common mechanism of immune escape in MCC. In one patient, delayed tumor regression coincided with endogenous effector immune activation and restoration of MCC HLA expression, implying that robust local responses could reverse HLA silencing. To overcome this barrier, we engineered CD4 and CD8 T TCR-MCC1 cells to coexpress CD8αβ and a CD200R-CD28 switch receptor, enabling CD4 T cell engagement and T cell costimulation. These modifications enhanced tumor infiltration, increased HLA expression, and improved control of HLA low MCC in vivo in mice. These findings support the feasibility of TCR-engineered cell therapy for MCPyV + MCC and provide a blueprint for overcoming immune evasion via targeted localized enhancement of antigen presentation.